Santhera Pharmaceuticals

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company’s lead asset AGAMREE® (vamorolone) is a dissociative steroid with a novel mode of action, for the treatment of patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids.